Vladimir Makarov

14PUBLICATIONS
154CO-AUTHORS
Infant and child healthMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Solid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jun 30, 2026
Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

|Feb 05, 2026
The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation.

Bridget Adcock, Moaath K Mustafa Ali, Emily C Zabor

|Jan 02, 2026
Tumor ecosystem and microbiome features associated with efficacy and resistance to avelumab plus chemoradiotherapy in head and neck cancer.

Nadeem Riaz, Tyler J Alban, Robert I Haddad

|Jan 02, 2026
Intratumoral bacteria are immunosuppressive and promote immunotherapy resistance in head and neck squamous cell carcinoma.

Natalie L Silver, Jin Dai, Travis D Kerr

|May 09, 2025
Impaired T cell and neoantigen retention in time-serial analysis of metastatic non-small cell lung cancer in patients unresponsive to TIL cell therapy.

Chao Wang, Xiaoqing Yu, Jamie K Teer

|May 01, 2025
Avelumab induces greater Fc-Fc receptor-dependent natural killer cell activation and dendritic cell crosstalk compared to durvalumab.

Nicole Osborne, Amit Rupani, Vladimir Makarov

Pageof 3

Frequent Collaborators

12 joint publications

Timothy Chan

5 joint publications

Tyler J Alban

5 joint publications

Fengshen Kuo

3 joint publications

Nadeem Riaz